Management discusses new data from the TakeAim Leukemia trial of Emavusertib, including data presented at the 64th Annual Meeting of ASH on a conference call to be held on December 12 at 10 am. Webcast Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CRIS: